Literature DB >> 11062066

Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase.

X Fang1, S Yu, R LaPushin, Y Lu, T Furui, L Z Penn, D Stokoe, J R Erickson, R C Bast, G B Mills.   

Abstract

Lysophosphatidic acid (LPA) is a naturally occurring phospholipid with multiple biological functions. In the present study, we demonstrate that, besides its mitogenic activity, LPA is a potent survival factor, preventing serum-deprivation-induced apoptosis in fibroblasts and other cell types. Both the proliferative effect and survival activity of LPA are sensitive to the action of pertussis toxin (PTX), indicating that both processes are mediated by G(i) protein(s). We therefore focused on the role of G(i)-protein-mediated signalling events in the promotion of cell survival by LPA. In addition to activation of mitogen-activated protein kinase (MAPK), LPA stimulates a modest PTX-sensitive phosphorylation/activation of the serine/threonine kinase Akt, a survival mediator downstream of phosphoinositide 3-kinase (PI3K). Inhibition of PI3K with LY 294002 or wortmannin resulted in a marked inhibition of LPA-induced DNA synthesis, and yet the survival activity of LPA decreased by only 20-30%, suggesting a limited input of the PI3K-Akt cascade in LPA-induced cell survival. In contrast, inhibition of MAPK activation by the MEK-1 inhibitor, PD 98059, blocked both the proliferative and survival effects of LPA. These results indicate that LPA promotes cell survival largely via G(i)-protein-mediated activation of ERK1/ERK2, or other PD 98059-sensitive member(s) of the MAPK family.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11062066      PMCID: PMC1221440     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  49 in total

1.  The biologically active phospholipid, lysophosphatidic acid, induces phosphatidylcholine breakdown in fibroblasts via activation of phospholipase D. Comparison with the response to endothelin.

Authors:  R L van der Bend; J de Widt; E J van Corven; W H Moolenaar; W J van Blitterswijk
Journal:  Biochem J       Date:  1992-07-01       Impact factor: 3.857

2.  VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling.

Authors:  K Gupta; S Kshirsagar; W Li; L Gui; S Ramakrishnan; P Gupta; P Y Law; R P Hebbel
Journal:  Exp Cell Res       Date:  1999-03-15       Impact factor: 3.905

3.  Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.

Authors:  Y Xu; Z Shen; D W Wiper; M Wu; R E Morton; P Elson; A W Kennedy; J Belinson; M Markman; G Casey
Journal:  JAMA       Date:  1998-08-26       Impact factor: 56.272

4.  Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax.

Authors:  E J Goetzl; Y Kong; B Mei
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

5.  Akt-dependent and -independent survival signaling pathways utilized by insulin-like growth factor I.

Authors:  G Kulik; M J Weber
Journal:  Mol Cell Biol       Date:  1998-11       Impact factor: 4.272

6.  Regulation of cell death protease caspase-9 by phosphorylation.

Authors:  M H Cardone; N Roy; H R Stennicke; G S Salvesen; T F Franke; E Stanbridge; S Frisch; J C Reed
Journal:  Science       Date:  1998-11-13       Impact factor: 47.728

7.  Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells.

Authors:  A Frankel; G B Mills
Journal:  Clin Cancer Res       Date:  1996-08       Impact factor: 12.531

8.  Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.

Authors:  Y Xu; D C Gaudette; J D Boynton; A Frankel; X J Fang; A Sharma; J Hurteau; G Casey; A Goodbody; A Mellors
Journal:  Clin Cancer Res       Date:  1995-10       Impact factor: 12.531

9.  Lysophosphatidic acid and apoptosis of nerve growth factor-differentiated PC12 cells.

Authors:  F W Holtsberg; M R Steiner; A J Bruce-Keller; J N Keller; M P Mattson; J C Moyers; S M Steiner
Journal:  J Neurosci Res       Date:  1998-09-15       Impact factor: 4.164

10.  Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation.

Authors:  M P Scheid; V Duronio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

View more
  29 in total

Review 1.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

2.  Pleiotropic phenotype of a genomic knock-in of an RGS-insensitive G184S Gnai2 allele.

Authors:  Xinyan Huang; Ying Fu; Raelene A Charbeneau; Thomas L Saunders; Douglas K Taylor; Kurt D Hankenson; Mark W Russell; Louis G D'Alecy; Richard R Neubig
Journal:  Mol Cell Biol       Date:  2006-09       Impact factor: 4.272

3.  Toward the three-dimensional structure and lysophosphatidic acid binding characteristics of the LPA(4)/p2y(9)/GPR23 receptor: a homology modeling study.

Authors:  Guo Li; Philip D Mosier; Xianjun Fang; Yan Zhang
Journal:  J Mol Graph Model       Date:  2009-04-19       Impact factor: 2.518

4.  Lysophosphatidic Acid Receptor Antagonism Protects against Diabetic Nephropathy in a Type 2 Diabetic Model.

Authors:  Ming-Zhi Zhang; Xin Wang; Haichun Yang; Agnes B Fogo; Brian J Murphy; Robert Kaltenbach; Peter Cheng; Bradley Zinker; Raymond C Harris
Journal:  J Am Soc Nephrol       Date:  2017-07-24       Impact factor: 10.121

Review 5.  Pathogenesis of Systemic Sclerosis.

Authors:  Debendra Pattanaik; Monica Brown; Bradley C Postlethwaite; Arnold E Postlethwaite
Journal:  Front Immunol       Date:  2015-06-08       Impact factor: 7.561

Review 6.  Role of the lysophospholipid mediators lysophosphatidic acid and sphingosine 1-phosphate in lung fibrosis.

Authors:  Barry S Shea; Andrew M Tager
Journal:  Proc Am Thorac Soc       Date:  2012-07

Review 7.  Heterotrimeric G proteins and apoptosis: intersecting signaling pathways leading to context dependent phenotypes.

Authors:  Vijay Yanamadala; Hideyuki Negoro; Bradley M Denker
Journal:  Curr Mol Med       Date:  2009-06       Impact factor: 2.222

Review 8.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

9.  Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.

Authors:  Shelley B Hooks; Phillip Callihan; Molly K Altman; Jillian H Hurst; Mourad W Ali; Mandi M Murph
Journal:  Mol Cancer       Date:  2010-11-02       Impact factor: 27.401

10.  Regulation of p53 expression, phosphorylation and subcellular localization by a G-protein-coupled receptor.

Authors:  L Solyakov; E Sayan; J Riley; A Pointon; A B Tobin
Journal:  Oncogene       Date:  2009-08-03       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.